Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#6082
AC Immune SA
2.9
3
-0.34%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
-0.34%
Mudança mensal
-17.93%
Mudança em 6 meses
+42.23%
Mudança anual
+14.45%
Fechamento anterior
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volume
17
Mercados
Ações
Cuidados de saúde
ACIU
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
366.71 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
1.33 B
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
Notícias
AC Immune inicia ensaio de fase 1 de inibidor de NLRP3 com penetração cerebral
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
Ações da AC Immune sobem após dados positivos de ensaio para doença de Parkinson
AC Immune stock rises after positive Parkinson’s disease trial data
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline